Company / SG&A Expense
Forte Biosciences, Inc. SG&A Expense History
FY2018-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$8.6M
FY2019
5-year range
$4.5M / $8.6M
FY2018-FY2019
Trend
+89.3%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$9M in FY2019.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2019, sg&a expense increased 89.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $8.6M | +89.3% |
| FY2018 | $4.5M | - |
As of FY2019 · SEC 10-K Annual Filings · Updated Jun 24, 2026